Co-Treatment of Erythroid Cells from β-Thalassemia Patients with CRISPR-Cas9-Based β(0)39-Globin Gene Editing and Induction of Fetal Hemoglobin

Gene editing (GE) is an efficient strategy for correcting genetic mutations in monogenic hereditary diseases, including β-thalassemia. We have elsewhere reported that CRISPR-Cas9-based gene editing can be employed for the efficient correction of the β(0)39-thalassemia mutation. On the other hand, ro...

Descripción completa

Detalles Bibliográficos
Autores principales: Cosenza, Lucia Carmela, Zuccato, Cristina, Zurlo, Matteo, Gambari, Roberto, Finotti, Alessia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601852/
https://www.ncbi.nlm.nih.gov/pubmed/36292612
http://dx.doi.org/10.3390/genes13101727

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601852/
https://www.ncbi.nlm.nih.gov/pubmed/36292612
http://dx.doi.org/10.3390/genes13101727

Ejemplares similares